Patient satisfaction with beclomethasone dipropionate nasal aerosol device with integrated dose counter during daily use

Allergy and Asthma Proceedings

Volumn 34, Issue 6, 2013, Pages 527-533

  Gross, Gary N ^a   Settipane, Russell A ^b   Ford, Linda B ^c   Kelley, Leith ^d   Tantry, Sudeesh K ^d  

^a Dallas Allergy & Asthma Center   (United States)

^b NASA HEADQUARTERS   (United States)

^c Asthma and Allergy Center   (United States)

^d Teva Branded Pharmaceutical Products R and D Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; NOSE SPRAY; PLACEBO;

ADOLESCENT; ADULT; AEROSOL; AGED; ALLERGIC RHINITIS; AQUEOUS SOLUTION; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; INHALER; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL DEVICE EASE OF USE AND SATISFACTION QUESTIONNAIRE; NOSE; NOSE DISEASE; PATIENT SATISFACTION; PERENNIAL RHINITIS; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AEROSOLS; AGED; AGED, 80 AND OVER; BECLOMETHASONE; CHILD; DELIVERY OF HEALTH CARE, INTEGRATED; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; RHINITIS, ALLERGIC, PERENNIAL; YOUNG ADULT;

EID: 84888413961     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2013.34.3706     Document Type: Article

References (25)

1. Greiner AN, Hellings PW, Rotiroti G, and Scadding GK. Allergic rhinitis. Lancet 378:2112-2122, 2011.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
3. Luskin AT, Blaiss MS, Farrar JR, et al. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: A white paper. Allergy Asthma Proc 32:168-177, 2011.
4. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008.
5. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 126:466-476, 2010.
6. Naclerio RM, Hadley JA, Stoloff S, and Nelson HS. Patient and physician perspectives on the attributes of nasal allergy medications. Allergy Asthma Proc 28:S11-S17, 2007.
7. Fromer LM, Ortiz G, Ryan SF, and Stoloff SW. Insights on allergic rhinitis from the patient perspective. J Fam Pract 61:S16-S22, 2012.
8. Edwards TB. Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Clin Ther 17:1032-1041, 1995.
9. U.S. Environmental Protection Agency (EPA). The Montreal protocol on substances that deplete the ozone layer. Available online at www.epa.gov/ozone/intpol/; accessed March 11, 2013.
10. Teva Respiratory, LLC. QNASL (beclomethasone dipropionate) nasal aerosol for intranasal use only prescribing information. Horsham, PA; June 2012.
11. Meltzer EO, Jacobs RL, LaForce CF, et al. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc 33:249-257, 2012.
12. Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev 14:109-116, 2005.
13. Bukstein D, Luskin AT, and Farrar JR. The reality of adherence to rhinitis treatment: Identifying and overcoming the barriers. Allergy Asthma Proc 32:265-271, 2011.
14. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 98:12-21, 2007.
15. Mahadevia PJ, Shah S, Leibman C, et al. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: A conjoint analysis. Ann Allergy Asthma Immunol 93:345-350, 2004.
16. Hankin C, Cox L, Lang D, et al. Medical costs and adherence in patients receiving aqueous versus pressurized aerosol formulations of intranasal corticosteroids. Allergy Asthma Proc 33:258-254, 2012.
17. Meltzer EO, Korenblat PE, Lanier BQ, et al. Device and integrated dose counter performance of beclomethasone dipropionate nasal aerosol during daily use. Allergy Asthma Proc 34:534-541, 2013.
18. Shah S, White M, Uryniak T, and O'Brien CD. The functionality of a budesonide/formoterol pressurized metered-dose inhaler with an integrated actuation counter. Allergy Asthma Proc 31:40-48, 2010.
19. Weinstein C, Staudinger H, Scott I, et al. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. Respir Med 105:979-988, 2011.
20. Given J, Taveras H, Iverson H, and Lepore M. Prospective, open-label assessment of albuterol sulfate hydrofluoroalkane metered-dose inhaler with new integrated dose counter. Allergy Asthma Proc 34:42-51, 2013.
21. Wasserman RL, Sheth K, Lincourt WR, et al. Real-world assessment of a metered-dose inhaler with integrated dose counter. Allergy Asthma Proc 27:486-492, 2006.
22. LaForce C, Weinstein C, Nathan RA, et al. Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination. J Asthma 48:625-631, 2011.
23. GlaxoSmithKline. Veramyst (fluticasone furoate) nasal spray prescribing information. Research Triangle Park, NC; August 2012.
24. Sunovion Pharmaceuticals, Inc. Zetonna (ciclesonide) nasal aerosol prescribing information. Marlborough, MA; January 2012.
25. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 136:S107--S124, 2007.